Abstract: Provided is a method of modifying a target site in the genome of a eukaryotic cell, the method comprising: (1) a step of introducing into the cell, introduction nucleic acids comprising (a) a template nucleic acid comprising a nucleic acid sequence encoding an RNA-guided nuclease, (b) a template nucleic acid comprising a nucleic acid sequence encoding a guide RNA, or a guide RNA, and (c) a template nucleic acid comprising a nucleic acid sequence encoding a selectable marker; and (2) a step of selecting a cell expressing the selectable marker, wherein the number of moles (C) of (c) the template nucleic acid comprising a nucleic acid sequence encoding a selectable marker, subjected to the step (1), is smaller than any of the number of moles (A) of (a) the template nucleic acid comprising a nucleic acid sequence encoding an RNA-guided nuclease and the number of moles (B) of (b) the template nucleic acid comprising a nucleic acid sequence encoding a guide RNA, or the guide RNA.

Abstract: The invention relates to the field of delivery of nucleic acid-based agents to immune cells.

Abstract: [Problem to be solved] The present invention provides an antibody-drug conjugate (ADC). The present invention also provides a conjugate of an anti-CD71 antibody or an antigen-binding fragment thereof with a drug. The present invention further provides a conjugate of Fab? with a drug. The present invention further provides a composition comprising the conjugate for delivering the drug to a tissue or a cell of muscle or the like. [Solution] A conjugate of an anti-CD71 antibody or an antigen-binding fragment thereof with a drug, and a conjugate of Fab? of an antibody with a drug.

Abstract: Provided is a method of modifying a target site in the genome of a eukaryotic cell, the method comprising: (1) a step of introducing into the cell, introduction nucleic acids comprising (a) a template nucleic acid comprising a nucleic acid sequence encoding an RNA-guided nuclease, (b) a template nucleic acid comprising a nucleic acid sequence encoding a guide RNA, or a guide RNA, and (c) a template nucleic acid comprising a nucleic acid sequence encoding a selectable marker; and (2) a step of selecting a cell expressing the selectable marker, wherein the number of moles (C) of (c) the template nucleic acid comprising a nucleic acid sequence encoding a selectable marker, subjected to the step (1), is smaller than any of the number of moles (A) of (a) the template nucleic acid comprising a nucleic acid sequence encoding an RNA-guided nuclease and the number of moles (B) of (b) the template nucleic acid comprising a nucleic acid sequence encoding a guide RNA, or the guide RNA.

Abstract: The invention relates to the field of delivery of nucleic acid-based agents to immune cells.

Abstract: The present invention provides a screening method/screening kit for an IL-13 production inhibitor, which comprises using (a) a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, or a salt thereof; and (b) a ligand capable of specifically binding to the protein; an IL-13 production inhibitor which is obtainable by said screening, and the like. The IL-13 production inhibitor which can be obtained by the screening of the present invention is useful as a prophylactic/therapeutic agent for, e.g., respiratory disease, etc.

Abstract: The invention relates to the field of delivery of nucleic acid-based agents to immune cells.

Abstract: The present invention provides a GPR receptor function regulator comprising the compound represented by the formula: [wherein ring A is an optionally substituted isocyclic or heterocyclic ring, P is a bond or spacer, ring D is an optionally substituted monocyclic aromatic ring which may be condensed with a 5- to 7-membered ring, V is a bond or the group represented by the formula —CR14?CR15— or —N?CR16— (wherein R14, R15 and R16 each represents a hydrogen atom or optionally substituted hydrocarbon group), Q is a bond or spacer, and W is a carboxyl or a group biologically equivalent to a carboxyl] or its salt or a prodrug thereof.

Abstract: The present invention provides a ligand to GPR8, in particular polypeptides capable of binding to GPR8 or its amides or esters, or salts thereof, as well as the DNA encoding for such polypeptides. The ligand to GPR8 of the present invention is useful in developing receptor-binding assay systems with the use of a GPR8 expression system, for screening candidate compounds for drugs such as preventive/therapeutic agents for obesity, appetite stimulants, and prolactin production inhibitors.

Abstract: The present invention provides a screening method/screening kit for an IL-13 production inhibitor, which comprises using (a) a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, or a salt thereof; and (b) a ligand capable of specifically binding to the protein; an IL-13 production inhibitor which is obtainable by said screening, and the like. The IL-13 production inhibitor which can be obtained by the screening of the present invention is useful as a prophylactic/therapeutic agent for, e.g., respiratory disease, etc.

Abstract: The present invention aims at providing a ligand to GPR8, its DNA, etc., and more particularly, a polypeptide capable of binding to GPR8 or its amides or esters, or salts thereof, as well as its DNA, etc. The ligand to GPR8 of the present invention is useful in developing a receptor-binding assay system with the use of a GPR8 expression system, screening candidate compounds for drugs such as preventive/therapeutic agents for obesity, appetite stimulants, prolactin production inhibitors, etc.

Abstract: The present invention relates to a screening method for a compound or a salt thereof that alters the binding property of MCH or a salt thereof to SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof, characterized by using MCH, a derivative or a salt thereof and SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof. The screening method of the present invention is useful for screening an SLT agonist, which can be used as an agent for promoting appetite (eating), and an SLT antagonist, which can be used as a prophylactic and/or therapeutic agent for obesity.

Abstract: The present invention relates to a screening method/screening kit for screening a compound or its salt that changes the binding properties of (a) a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 19, its partial peptides, or salts thereof, and (b) a ligand capable of binding specifically to the protein; compounds obtained by the screening or salts thereof; pharmaceuticals comprising the compounds or salts thereof; a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 19; etc. The compounds obtained by the screening of the present invention are useful as agents for the prevention/treatment of, for example, neurodegenerative diseases, immunological diseases, edema, acid indigestion, etc.

Abstract: The present invention provides a ligand to GPR8, in particular polypeptides capable of binding to GPR8 or its amides or esters, or salts thereof, as well as DNA, encoding for such polypeptides. The ligand to GPR8 of the present invention is useful in developing a receptor-binding assay system with the use of a GPR8 expression system, for screening candidate compounds for drugs such as preventive/therapeutic agents for obesity, appetite stimulants, and prolactin production inhibitors.

Abstract: A novel polypeptide having a cell death inhibitory activity and use thereof is provided. The polypeptide and the polynucleotide encoding it can be used as a diagnostic, therapeutic or prophylactic agent for various diseases and disorders. Certain suitable diseases and disorders which may be diagnosed, treated, or prevented with the polypeptide and the polynucleotide encoding it are selected from neurodegenerative diseases, brain dysfunctions, cancers, immunological disease, infections, gastrointestinal diseases, circulatory diseases, and endocrine diseases. The polypeptide and the polynucleotide encoding it can be used as a cell death inhibitor.

Abstract: The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist which can be used not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, and the like, and an SLC-1 antagonist which can be used not only as an antiobestic agents (drug), an appetite (eating) modulator, and the like, but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Wili syndrome and the like.

Abstract: The present invention relates to a screening method/screening kit for screening a compound or its salt that changes the binding properties of (a) a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 19, its partial peptides, or salts thereof, and (b) a ligand capable of binding specifically to the protein; compounds obtained by the screening or salts thereof; pharmaceuticals comprising the compounds or salts thereof; a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 19; etc. The compounds obtained by the screening of the present invention are useful as agents for the prevention/treatment of, for example, neurodegenerative diseases, immunological diseases, edema, acid indigestion, etc.

Abstract: The present invention aims at providing a ligand to GPR8, its DNA, etc., and more particularly, a polypeptide capable of binding to GPR8 or its amides or esters, or salts thereof, as well as its DNA, etc. The ligand to GPR8 of the present invention is useful in developing a receptor-binding assay system with the use of a GPR8 expression system, screening candidate compounds for drugs such as preventive/therapeutic agents for obesity, appetite stimulants, prolactin production inhibitors, etc.

Abstract: The present invention relates to a novel polypeptide having a cell death inhibitory activity and use thereof, etc.

Abstract: The present invention relates to a screening method for a compound or a salt thereof that alters the binding property of MCH or a salt thereof to SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof, characterized by using MCH, a derivative or a salt thereof and SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof. The screening method of the present invention is useful for screening an SLT agonist, which can be used as an agent for promoting appetite (eating), and an SLT antagonist, which can be used as a prophylactic and/or therapeutic agent for obesity.